Rasagiline

Rasagiline is a pharmaceutical-grade active ingredient classified as an irreversible MAO-B Inhibitor Anti-Parkinsonian agent. Mediocon Inc supplies high-purity Rasagiline API conforming to IP / BP / EP / USP specifications, manufactured in our GMP-certified facility in Aurangabad, Maharashtra, India.

Rasagiline is an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), used in the treatment of Parkinson's disease both as monotherapy and as adjunct to levodopa. By inhibiting dopamine breakdown, rasagiline improves motor symptoms and extends levodopa efficacy, delaying disease progression.

Key Features

• High-purity pharmaceutical grade API
• IP/BP/EP/USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Parkinson's disease monotherapy (early stage)
• Adjunctive therapy with levodopa
• Motor fluctuation management in PD
• Neuroprotective potential in Parkinson's disease

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings